Author

B. M. Hauser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 11 Bioengineering· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Research Focus:host-pathogen & immune response· 9 Organism:human· 7 Assay:proteomics· 7 Organism:mouse· 6 Research Focus:cell type annotation· 4 Research Focus:drug response / drug discovery· 3 Research Focus:differential expression· 2

Frequent Co-Authors

J. Feldman· 12 shared A. G. Schmidt· 10 shared T. M. Caradonna· 6 shared A. B. Balazs· 5 shared D. Lingwood· 5 shared E. C. Lam· 4 shared M. Sangesland· 4 shared K. J. St. Denis· 3 shared

Activity by Year

2020-2023 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

12 shared papersImmunology

J. Feldman

Mutual co-authors in cluster

Author profile →

13 papers

Recent·Most cited

Characterization of SARS-CoV-2 Convalescent Patients' Serological Repertoire Reveals High Prevalence of Iso-RBD Antibodies

N. C. Curtis, S. Shin, A. P. Hederman, R. I. Connor, W. F. Wieland-Alter, S. Ionov, J. Boylston, J. Rose, M. Sakharkar, D. B. Dorman, J. A. Dessaint, L. L. Gwilt, A. R. Crowley, J. Feldman, B. M. Hauser, , J. Lee

This study characterizes the serological repertoire of SARS-CoV-2 convalescent patients, revealing a high prevalence of iso-RBD antibodies that do not recognize prefusion-stabilized S, and shows that vaccination with prefusion-stabilized S reduces their prevalence.

bioRxiv · Sep 8, 2023 · PreprintImmunology

Heterologous sarbecovirus receptor binding domains as scaffolds for SARS-CoV-2 receptor binding motif presentation

B. M. Hauser, M. Sangesland, E. C. Lam, K. J. St. Denis, M. L. Sheehan, M. L. Vu, A. H. Cheng, A. B. Balazs, D. Lingwood, A. Schmidt

This study designs immunogens by grafting SARS-2 RBM onto heterologous sarbecovirus scaffolds to elicit broad neutralizing antibodies against sarbecoviruses.

bioRxiv · Aug 21, 2023Immunology

Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds

E.-C. Wamhoff, L. Ronsard, J. Feldman, G. A. Knappe, B. M. Hauser, A. Romanov, E. Lam, K. St. Denis, J. Boucau, A. K. Barczak, A. B. Balazs, A. Schmidt, D. Lingwood, M. Bathe

This study shows DNA origami scaffolds enhance antibody responses to SARS-CoV-2 RBD without inducing immune memory against the scaffold itself, compared to protein-based VLPs.

bioRxiv · Aug 16, 2022Immunology

An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice

F. Borriello, E. Nanishi, H.-S. Seo, T. R. OMeara, M. E. McGrath, Y. Saito, R. E. Haupt, J. Chen, J. Diray-Arce, K. Song, A. Z. Xu, T. M. Caradonna, J. Feldman, B. M. Hauser, A. G. Schmidt, , O. Levy

This study identifies an adjuvanted SARS-CoV-2 RBD nanoparticle that induces neutralizing antibodies and full protection in aged mice.

bioRxiv · Sep 9, 2021 · PreprintImmunology

Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity

E. Nanishi, F. Borriello, T. R. O'Meara, M. E. McGrath, Y. Saito, R. E. Haupt, H.-S. Seo, S. D. van Haren, B. Brook, J. Chen, J. Diray-Arce, S. Doss-Gollin, M. De Leon, K. Chew, M. Menon, , D. J. Dowling

This study evaluates AH:CpG adjuvant's ability to enhance RBD vaccine efficacy in aged mice and human elder cells, showing strong neutralizing antibody responses and cytokine production.

bioRxiv · May 20, 2021Immunology

The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection

D. R. Sandoval, T. Mandel Clausen, C. Nora, J. A. Magida, A. P. Cribbs, A. Denardo, A. E. Clark, A. F. Garretson, J. K. C. Coker, A. Narayanan, S. A. Majowicz, M. Philpott, C. Johansson, J. E. Dunford, C. B. Spliid, , Mazitsch

This study identifies halofuginone as a potent inhibitor of SARS-CoV-2 infection and replication by reducing heparan sulfate biosynthesis and suppressing viral replication.

bioRxiv · Mar 22, 2021 · PreprintMicrobiology

Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif

B. M. Hauser, M. Sangesland, K. J. St. Denis, I. W. Windsor, J. Feldman, E. C. Lam, T. Kannegieter, A. B. Balazs, D. Lingwood, A. G. Schmidt

This study designs immunogens that focus immune responses to the SARS-CoV-2 receptor binding motif, enhancing neutralizing antibody breadth against related sarbecoviruses.

bioRxiv · Mar 15, 2021 · PreprintImmunology

Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike

P. Tong, A. Gautam, I. Windsor, M. Travers, Y. Chen, N. Garcia, N. Whiteman, L. McKay, F. J. N. Lelis, S. Habibi, Y. Cai, L. J. Rennick, W. P. Duprex, K. McCarthy, C. L. Lavine, , D. R. Wesemann

The paper maps memory B cell receptors against SARS-CoV-2 spike variants, identifying 7 mAb competition groups and their epitopic regions, and shows their cross-reactivity and neutralization properties.

bioRxiv · Mar 10, 2021Immunology

Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses

J. Feldman, J. Bals, C. Altomare, K. S. Denis, E. C. Lam, B. M. Hauser, L. Ronsard, M. Sangesland, T. B. Moreno, V. Okonkwo, N. Hartojo, A. B. Balazs, G. Bajic, D. Lingwood, A. G. Schmidt

The paper isolates naive B cells targeting SARS-CoV-2 RBD and shows they can neutralize the virus and variants.

bioRxiv · Feb 2, 2021Immunology

Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates

N. Zabaleta, W. Dai, U. Bhatt, J. A. Chichester, J. Sanmiguel, R. Estelien, K. T. Michalson, C. Diop, D. Maciorowski, W. Qi, E. Hudspeth, A. Cucalon, C. D. Dyer, M. B. Pampena, J. J. Knox, , L. H. Vandenberghe

This paper evaluates an AAV-based COVID-19 vaccine in mice and non-human primates, showing sustained neutralizing antibodies and memory T-cells, with room-temperature stability and scalable production.

bioRxiv · Jan 5, 2021 · PreprintImmunology

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

D. Li, R. J. Edwards, K. Manne, D. R. Martinez, A. Schafer, S. M. Alam, K. Wiehe, X. Lu, R. Parks, L. L. Sutherland, T. H. Oguin, C. McDanal, L. G. Perez, K. Mansouri, S. M. C. Gobeil, , Petzol

This study examines SARS-CoV-2 neutralizing and infection-enhancing antibodies, showing in vitro enhancement does not always lead to in vivo disease enhancement, but can cause increased lung inflammation in monkeys.

bioRxiv · Dec 31, 2020 · PreprintImmunology

Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies

B. M. Hauser, M. Sangesland, E. C. Lam, K. J. St. Denis, J. Feldman, A. S. Yousif, T. M. Caradonna, T. Kannegieter, A. B. Balazs, D. Lingwood, A. G. Schmidt

This study shows that a cocktail of trimeric sarbecovirus receptor binding domains elicits broadly neutralizing antibodies against multiple sarbecoviruses, including in the context of prior SARS-CoV-2 immunity.

bioRxiv · Dec 7, 2020 · PreprintImmunology

Rapid generation of potent antibodies by autonomous hypermutation in yeast

A. Wellner, C. McMahon, M. S. A. Gilman, J. R. Clements, S. Clark, K. M. Nguyen, M. H. Ho, J.-E. Shin, J. Feldman, B. M. Hauser, T. M. Caradonna, L. M. Wingler, A. G. Schmidt, D. S. Marks, J. Abraham, , C. C. Liu

This paper introduces AHEAD, a yeast-based system for rapid antibody generation through autonomous hypermutation, achieving high-affinity antibodies against SARS-CoV-2 and other targets in just 2 weeks.

bioRxiv · Nov 11, 2020Bioengineering